• Accelerating Anti-Tuberculosis Drug Development With A Population-Based Lung Model

    Clinical Informatics News | To support recent drug development efforts, Certara, in collaboration with the Critical Path to TB Drug Regimens (CPTR), introduced a pharmacokinetic/pharmacodynamic lung model for its Simcyp Population-based Simulator v16, which can predict how drugs will be dispersed in the lungs at different stages of TB infection.

    May 29, 2018

  • Veeva, WCG, Charles River, And More: News From May 2018

    Clinical Informatics News | May was full of exciting news in the clinical trial and healthcare community, including partnerships, products, and promotions from Veeva, WCG, Charles River, and more.

    May 23, 2018

  • ICH E6 R2 – The Clinical R&D Industry’s Response

    Clinical Informatics News Contributed Commentary | For decades now the complexity, cost, and duration of clinical development have been steadily increasing while profit margins for the industry have been dwindling. This crisis persists and is compounded by inefficient traditional methods of managing clinical trial quality. The ICH Good Clinical Practice Guidance Integrated Addendum (ICH E6 R2) provides a unified standard for the European Union, Japan, the United States, Canada, and Switzerland.

    May 22, 2018

  • Are You And Your Primary Care Doc Ready To Talk About Your DNA?

    Kaiser Health News |  The Pennsylvania-based health chain Geisinger plans to offer DNA sequencing as part of regular patient care.

    May 22, 2018

  • Is There Life After GDPR?

    Forbes |  GDPR may limit what advertisers can do, but there are other ways to target specific consumers.

    May 16, 2018

  • Why Now Is the Right Time To Take Action On eSource

    Clinical Informatics News Contributed Commentary | When something new comes along, most tend to take a cautious approach, observing early adopters from afar before deciding whether to make their own investments. These next-wave adopters have a perceived benefit of proven products without the anxiety of being “the first.” In clinical research, eSource has now crossed this chasm from early adoption to mainstream criticality.

    May 16, 2018

  • Democratic Senator Opens Probe Into Novartis Over Its Dealings With Trump's Attorney

    STAT |  In a letter to Novartis, U.S. Sen. Ron Wyden (D-Ore.) suggested the payments may have been linked to a groundbreaking Novartis cancer treatment that was being reviewed last year by the FDA. And he also noted the drug maker was holding talks last year with the CMS about a unique reimbursement deal for the medication.

    May 11, 2018